| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5998380 | JANSSEN PHARMS | Treatment of migraine |
Oct, 2015
(8 years ago) | |
| US6503884 | JANSSEN PHARMS | Migraine treatment method using topiramate and related compounds |
Oct, 2015
(8 years ago) | |
| US7018983 | JANSSEN PHARMS | Treatment of migraine |
Oct, 2015
(8 years ago) | |
| US7498311 | JANSSEN PHARMS | Treatment of migraine |
Oct, 2015
(8 years ago) | |
|
US7018983 (Pediatric) | JANSSEN PHARMS | Treatment of migraine |
Apr, 2016
(8 years ago) | |
|
US6503884 (Pediatric) | JANSSEN PHARMS | Migraine treatment method using topiramate and related compounds |
Apr, 2016
(8 years ago) | |
|
US7498311 (Pediatric) | JANSSEN PHARMS | Treatment of migraine |
Apr, 2016
(8 years ago) | |
|
US5998380 (Pediatric) | JANSSEN PHARMS | Treatment of migraine |
Apr, 2016
(8 years ago) | |
| US7125560 | JANSSEN PHARMS | Pharmaceutical composition of topiramate |
Mar, 2019
(5 years ago) | |
|
US7125560 (Pediatric) | JANSSEN PHARMS | Pharmaceutical composition of topiramate |
Sep, 2019
(4 years ago) | |
Topamax Sprinkle is owned by Janssen Pharms.
Topamax Sprinkle contains Topiramate.
Topamax Sprinkle has a total of 10 drug patents out of which 10 drug patents have expired.
Expired drug patents of Topamax Sprinkle are:
- US5998380
- US6503884
- US7018983
- US7498311
- US7018983*PED
- US6503884*PED
- US7498311*PED
- US5998380*PED
- US7125560
- US7125560*PED
Topamax Sprinkle was authorised for market use on 26 October, 1998.
Topamax Sprinkle is available in capsule;oral dosage forms.
Topamax Sprinkle can be used as prophylactic treatment of migraine, treatment of seizures.
The generics of Topamax Sprinkle are possible to be released after 01 September, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 15, 2014 |
| Pediatric Exclusivity(PED) | Jun 22, 2013 |
| M(M-54) | Dec 22, 2012 |
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 26 October, 1998
Treatment: Prophylactic treatment of migraine; Treatment of seizures
Dosage: CAPSULE;ORAL
TOPAMAX SPRINKLE family patents
